Source: NICE
Area: Evidence > Guidelines
NICE has issued final guidance (TA 274) supporting the use of ranibizumab for treating visual impairment due to diabetic macular oedema (DMO) only if:
. the eye has a central retinal thickness of 400 micrometres or more at the start of treatment and
. the manufacturer provides ranibizumab with the discount agreed in the patient access scheme (as revised in 2012).
NICE conducted a rapid review of the original guidance (TA 237; November 2011) because the manufacturer submitted a revised Patient Access Scheme, together (Read more...)
Uncategorized